Heersink School of Medicine have published a study in the Journal of the American Heart Association that focuses on how the ...

The FDA has accepted for review the New Drug Application for aficamten for the treatment of obstructive hypertrophic cardiomyopathy.

Methods: Members of the Hypertrophic Cardiomyopathy Association ... demographic and self-reported clinical information, and types and triggers of symptoms. Respondents reported physical and ...

The FDA has accepted a new drug application for aficamten, a new obstructive hypertrophic cardiomyopathy drug. A goal date ...

PDUFA Target Action Date Set for September 26, 2025SOUTH SAN FRANCISCO, Calif., Dec. 02, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated ...

Favorable short- and long-term outcomes are seen in patients with hypertrophic cardiomyopathy who receive septal reduction therapy.

Two New Analyses from SEQUOIA-HCM Demonstrate Treatment with Aficamten Improves Post-Exercise Oxygen Uptake Recovery and Quality of LifeNew Data ...

“That used to be true, but there have been huge advances in clinical care ... with obstructive forms of hypertrophic ...

Hypertrophic cardiomyopathy (HCM) is an uncommon disease with significant consequences. Since the 1950s, major strides in understanding its etiology and pathogenesis have led to improved ...

With Danon disease, which is thought to account for about 5% of pediatric forms of hypertrophic cardiomyopathy, symptoms usually ... fact that therapy had a net clinical benefit and delayed ...

Objective Current guidelines recommend precautionary disqualification from competitive sports in patients with hypertrophic cardiomyopathy (HCM ... gender balance, symptoms, ECG abnormalities, extent ...

With its first AAV gene therapy program, DiNA-001, in development for the treatment of MYBPC3 hypertrophic cardiomyopathy ... to heart failure. While cardiomyopathy symptoms can often be ...